Paul M Chapman

Address:

490 Maple Grv Rd, Moscow, PA 18444

Phone:

(570)8424473

VIN:

5N1AN08W47C502917

Make:

NISSAN

Model:

XTERRA

Year:

2007

US Patent:

6432402, Aug 13, 2002

Filed:

May 23, 1995

Appl. No.:

08/447412

Inventors:

Paul B. Chapman - New York NY
Alan N. Houghton - New York NY

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

A61K 39395

US Classification:

4241311, 4241301, 4241331, 4241841, 4241971, 42419711, 435325, 435326, 435327, 435346, 5303871, 5303872, 5303873, 5303875, 5303881, 53038825, 5303891, 5303893, 530810, 530808, 530806

Abstract:

The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.

US Patent:

6805862, Oct 19, 2004

Filed:

Jun 7, 1995

Appl. No.:

08/488549

Inventors:

Paul B. Chapman - New York NY
Alan N. Houghton - New York NY

Assignee:

Sloan-Kattering Institute For Cancer Research - New York NY

International Classification:

A61K 39395

US Classification:

4241311, 4241371, 4241841, 4241431, 4241551, 5303872, 5303877, 5303888, 53038885, 514885

Abstract:

The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglio-side-specific antibody attached to a carrier.

US Patent:

7442507, Oct 28, 2008

Filed:

Jan 24, 2006

Appl. No.:

11/338615

Inventors:

David Polsky - Ardsley NY, US
Iman Osman - Port Liberte NJ, US
Paul B. Chapman - New York NY, US

Assignee:

New York University School of Medicine - New York NY
Memorial Sloan-Kettering Cancer Center - New York NY

International Classification:

C12Q 1/68

US Classification:

435 6, 435 911, 435 912

Abstract:

The present invention relates to a method for detecting the presence of circulating mutant BRAF DNA, which may be present in circulating melanoma cells or as DNA shed from tumor cells. Methods, compositions and kits which employ one or more sets of BRAF mutant specific primer pairs for detection of circulating mutant BRAF DNA are presented. Also provided are methods for diagnosing and/or determining stage/progression of a melanoma in a mammal based on detection of a BRAF mutant nucleic acid sequence. Such methods are also well suited to monitoring disease activity in patients with active disease or those in remission.

US Patent:

8207308, Jun 26, 2012

Filed:

Aug 16, 2009

Appl. No.:

12/541958

Inventors:

Paul Chapman - New York NY, US
Lisa Davidson - Edingburgh, GB
José W. Saldanha - Middlesex, GB

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

C12P 21/08

US Classification:

5303873, 5303877, 5303888, 5303913

Abstract:

The present invention is related to complementarity determining region (cdr)-grafted humanized r24 antibodies that bind to the gd3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine r24 antibody, and the humanized antibodies are useful in treating cancer (e. g. Melanoma).

US Patent:

20030035797, Feb 20, 2003

Filed:

Aug 13, 2002

Appl. No.:

10/218725

Inventors:

Paul Chapman - New York NY, US
Alan Houghton - New York NY, US

Assignee:

Sloan-Kettering Institute for Cancer Research

International Classification:

A61K039/395
C12N005/06
C07K016/44

US Classification:

424/131100, 530/387200, 435/327000

Abstract:

The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.

US Patent:

20120276046, Nov 1, 2012

Filed:

Jun 22, 2012

Appl. No.:

13/530761

Inventors:

Paul Chapman - New York NY, US
Lisa Davidson - Edingburgh, GB
José W. Saldanha - Enfield, GB

Assignee:

SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY

International Classification:

C07K 16/18
A61K 38/20
C12N 5/10
A61P 35/00
C12N 15/79
A61K 39/395
C12N 15/13

US Classification:

424 852, 5303897, 5303913, 4241741, 536 2353, 4353201, 435349, 435419, 435325

Abstract:

The present invention is related to complementarity determining region (CDR)-grafted humanized R24 antibodies that bind to the GD3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine R24 antibody, and the humanized antibodies are useful in treating cancer (e.g. melanoma).

US Patent:

55299229, Jun 25, 1996

Filed:

May 22, 1995

Appl. No.:

8/445906

Inventors:

Paul B. Chapman - New York NY
Alan N. Houghton - New York NY

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

C12N 520
C07K 1642

US Classification:

43524027

Abstract:

The invention provides an anti-idiotypic monoclonal antibody, IgG2b subclass, which specifically induces an immune response against the GD. sub. 3 ganglioside and specifically binds to the binding site of the R24 antibody.

US Patent:

51046520, Apr 14, 1992

Filed:

Jul 5, 1990

Appl. No.:

7/549238

Inventors:

Alan N. Houghton - New York NY
Karl Welte - New York NY
Glenn Miller - Port Washington NY
Paul Chapman - New York NY
Lloyd J. Old - New York NY

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

A61K 3702
A61K 3900
C12N 502

US Classification:

424 852

Abstract:

Cell surface gangliosides are presumed to play a role in cell growth and differentiation. Using monoclonal antibodies directed against G. sub. D3, a disialoganglioside expressed predominantly by cells of neuroectodermal origin, we have found that G. sub. D3 is expressed by a subpopulation of cells of the immune system including: a) fetal thymocytes in subcortical regions and near vessels, 2) lymph node lymphocytes in interfollicular areas and near vessels, and 3) a small subset of T cells in the peripheral blood. Mouse monoclonal antibodies (two IgGs, one IgM and F(ab'). sub. 2 fragments) reacting with G. sub. D3 were found to stimulate proliferation of T cells derived from peripheral blood. Proliferation induced by binding to G. sub. D3 could be augmented by exogenous IL-2, PMA, PHA or Protein A.